Business Description
CytoSorbents Corp
NAICS : 621511
SIC : 3841
ISIN : US23283X2062
Total Employee Number:
129Description
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
Financial Strength
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 0.16 | |||||
Equity-to-Asset | 0.05 | |||||
Debt-to-Equity | 13.34 | |||||
Debt-to-EBITDA | -3.76 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -10.38 | |||||
Beneish M-Score | -3.31 | |||||
WACC vs ROIC | ||||||
Growth Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -3.8 | |||||
3-Year EBITDA Growth Rate | 53.5 | |||||
3-Year EPS without NRI Growth Rate | 30.7 | |||||
3-Year FCF Growth Rate | 36.1 | |||||
3-Year Book Growth Rate | -51.2 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 12.76 |
Momentum Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 41.42 | |||||
9-Day RSI | 42.39 | |||||
14-Day RSI | 42.33 | |||||
3-1 Month Momentum % | -32.62 | |||||
6-1 Month Momentum % | -38.75 | |||||
12-1 Month Momentum % | -63.95 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 1.09 | |||||
Quick Ratio | 0.81 | |||||
Cash Ratio | 0.3 | |||||
Days Inventory | 138.7 | |||||
Days Sales Outstanding | 73.67 | |||||
Days Payable | 106.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -12.7 | |||||
Shareholder Yield % | -5.36 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | 71.01 | |||||
Operating Margin % | -36.01 | |||||
Net Margin % | -31.85 | |||||
EBITDA Margin % | -20.93 | |||||
FCF Margin % | -28.47 | |||||
OCF Margin % | -27.08 | |||||
ROE % | -137 | |||||
ROA % | -25.84 | |||||
ROIC % | -42.86 | |||||
3-Year ROIIC % | -565.14 | |||||
ROC (Joel Greenblatt) % | -40 | |||||
ROCE % | -27.04 | |||||
Moat Score | 3 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 0.66 | |||||
PB Ratio | 10.89 | |||||
EV-to-EBIT | -5.16 | |||||
EV-to-Forward-EBIT | -5.03 | |||||
EV-to-EBITDA | -6.22 | |||||
EV-to-Forward-EBITDA | -6.87 | |||||
EV-to-Revenue | 1.3 | |||||
EV-to-Forward-Revenue | 1.24 | |||||
EV-to-FCF | -4.57 | |||||
Price-to-GF-Value | 0.43 | |||||
Price-to-Median-PS-Value | 0.09 | |||||
Earnings Yield (Greenblatt) % | -19.38 | |||||
FCF Yield % | -44.19 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CTSO
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
CytoSorbents Corp Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 37.2 | ||
| EPS (TTM) ($) | -0.19 | ||
| Beta | 1.2057 | ||
| 3-Year Sharpe Ratio | -0.64 | ||
| 3-Year Sortino Ratio | -0.95 | ||
| Volatility % | 58.08 | ||
| 14-Day RSI | 42.33 | ||
| 14-Day ATR ($) | 0.055069 | ||
| 20-Day SMA ($) | 0.415095 | ||
| 12-1 Month Momentum % | -63.95 | ||
| 52-Week Range ($) | 0.3504 - 1.22 | ||
| Shares Outstanding (Mil) | 62.84 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
CytoSorbents Corp Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
CytoSorbents Corp Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings conference call for 2026 | 2026-11-13 16:30 | In 125 days | ||
| Third quarter earnings results for 2026 | 2026-11-13 | In 124 days | ||
| General meeting for 2026 | 2026-08-13 10:00 | In 33 days | ||
| Second quarter earnings conference call for 2026 | 2026-08-07 16:30 | In 27 days | ||
| Second quarter earnings results for 2026 | 2026-08-07 | In 26 days | ||
| Life Sciences Virtual Investor Forum | 2026-06-24 11:30 | 0.43 (+4.56%) | ||
| First quarter earnings conference call for 2026 | 2026-05-13 16:30 | 0.59 (-5.50%) | ||
| First quarter earnings results for 2026 | 2026-05-13 | 0.59 (-5.50%) | ||
| Annual report for 2025 | 2026-03-30 | 0.59 (-4.35%) | ||
| Fourth quarter earnings conference call for 2025 | 2026-03-25 16:30 | 0.70 (+0.12%) |
Show
Entries
CytoSorbents Corp Frequently Asked Questions
What is CytoSorbents Corp(CTSO)'s stock price today?
The current price of CTSO is $0.38. The 52 week high of CTSO is $1.22 and 52 week low is $0.35.
When is next earnings date of CytoSorbents Corp(CTSO)?
The next earnings date of CytoSorbents Corp(CTSO) is 2026-08-07 Est..
Does CytoSorbents Corp(CTSO) pay dividends? If so, how much?
CytoSorbents Corp(CTSO) does not pay dividend.
Guru Commentaries on NAS:CTSO
No articles.
Press Release
Articles on CytoSorbents Corp
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers